Research Study

Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis
Principal Investigator 
Anthony Traboulsee

Overview

Body Locations and Systems 
Multiple Sclerosis
ClinicalTrials.gov# 
NCT03996291
Status 
Closed for Recruitment
Study Start/End 
Nov 12, 2019 to Jan 31, 2025
Locations 
UBC Hospital
Name/Title 
Camille Hunt, Research Coordinator
Phone 
604-827-1892
Email Address 
camille.hunt@ubc.ca
Purpose of Study 

The purpose of this study is to define a safe optimal dose or SAR442168, a small molecule,oral, once daily, CNS-penetrating, irreversible covalent inhibitor of BTK in participants with relapsing multiple sclerosis.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.